BACKGROUND: Platelet storage lesions are structural and biochemical changes in platelet concentrates (PCs), and depend on variables in collection and processing, as well as secondary procedures and storage conditions; such lesions can be mitigated by the use of platelet additive solutions (PASs).
STUDY DESIGN AND METHODS:
This study investigated release of the inflammatory markers sCD40L and sCD62P by single-donor apheresis platelet concentrates (SDA-PCs) and buffy coat-derived pooled platelet concentrates (PPCs) before and after storage. SDA-PC and PPC samples (n = 9089) processed by various methods and stored for different durations were obtained following production in one regional setting, the French National Blood Service. Soluble factors were quantified in PC supernatants immediately after processing and at the time of delivery, using biological testing technology (Luminex).
RESULTS: SDA-PCs appeared more activated than
PPCs at the end of the production step (i.e., prior to storage); however, proinflammatory soluble factors exhibited greater increases in PPCs than in SDA-PCs during storage. In SDA-PCs, PAS-D (65%) led to reduced secretion of sCD62P, but favored secretion of sCD40L, compared with the alternative PAS-E.
CONCLUSION:
These data stress the importance of the production (processing) steps of PC manufacture and of storage. The extent to which they affect patient outcomes awaits further investigation in clinical studies.
P
latelets are nonnucleated cellular elements with roles in both hemostasis and inflammation. 1 Platelet concentrates (PCs) processed for transfusion contain numerous secretory products that have expected influence on hemostasis but also effects on innate immunity. 2 Biological response modifiers (BRMs) increase during storage in supernatants of transfusion-grade PCs 3-5 and can even affect transfusion profiles. 6 BRM secretion profiles can affect the pathogenic condition of recipients. 4, 5 Some BRMs are reported to be instrumental in triggering inflammatory responses in recipients when their gross levels exceed a threshold (this finding was determined in model animals, 4 and its clinical relevance is unknown).
This study compared single-donor apheresis platelet concentrates (SDA-PCs) and whole blood, buffy coat-derived, pooled PCs (PPCs), and investigated BRM secretions that reflect storage lesions, 7 focusing on the soluble inflammatory platelet markers sCD40L and sCD62P, as these BRMs are considered indicative of platelet metabolism and activation. 8, 9 We also compared two platelet additive solutions (PASs), PAS-D and PAS-E, for SDA-PC preparation; PPCs were processed in PAS-D only. Storage length was also examined with respect to BRM secretion. The methods of preparation of SDA-PCs and PPCs differ in terms of centrifugation and filtration protocols and have been well described. 10, 11 This study was a well-powered ex vivo investigation of PCs processed for transfusion, including almost 9100 samples (SDA-PCs, n = 3876 vs. PPCs, n = 5213).
MATERIALS AND METHODS

PC processing
SDA-PCs or PPCs were collected from anonymous blood donors who volunteered to provide blood for research purposes and signed a consent form after receiving specific information. 4 Collection is performed by means of blood cell separators characterized by a continuous flow or an intermittent flow. The key difference between the blood cell separators relates to the blood flow from patient to separator and back to patient. Continuous-flow cell separators continuously centrifuge the incoming blood while returning the processed blood through a second venous line. Intermittent-flow cell separators work by centrifuging repeated batches of blood in subsequent cycles. After separation, the white blood cells are taken and the processed blood is returned to the patient through the same venous line used for drawing the blood. Methods for collecting SDA-PCs were reported previously 4 ; briefly, blood was collected on anticoagulant citrate dextrose solution A using a continuous-flow cell separator (Trima, Gambro BCT) or an intermittent-flow cell separator (MCS, Haemonetics). The distribution of SDA-PCs was 6.4% for MCS and 93.6% for Trima. All PCs were automatically resuspended in 35% autologous donor plasma and 65% PAS (PAS-D, Intersol, Fenwal; or PAS-E, SSP+, MacoPharma). PPCs were prepared as pools of five ABO and RhD-identical buffy coats, using an
Optipress device with top and bottom separation (Baxter Healthcare Corporation); they were resuspended in 35% PAS-D. PPCs were leukoreduced by filtration immediately after pooling (prestorage). 12 PCs were stored at 22 C AE 2 C under gentle rotation and shaking (60 rpm) for a maximum of 5 days before being issued for transfusion. PC supernatant samples were collected after centrifugation (402 × g; 10 min), as part of a research protocol detailed in Cognasse and colleagues, 13 and aliquots frozen at −80 C. For this study, 9089 samples were collected, corresponding to different steps of processing and storage ( Table 1) .
Quantification of soluble proteins
The levels of soluble CD40L (sCD40L-HCYTOMAG-60 K; minimum detectable concentrations: 5.1 pg/mL) and CD62P (sCD62P-HCVD2MAG-67 K; minimum detectable concentrations: 0.244 ng/mL) were quantified in PC supernatants using biological testing technology (Luminex, Millipore), according to the manufacturer's instructions, using a suspension array system (Bio-Plex 200, Bio-Plex Manager software, Bio-Rad).
4,5
Statistical analyses
Multiple comparisons were performed by two-way analysis of variance using the Bonferroni correction. For all tests, p values of less than 0.05 were considered significant. Results are presented as scatter plots and means AE standard error of the mean. Statistical analyses were performed using computer software (GraphPad Prism, GraphPad Software, Inc.).
RESULTS
From March 2013 to April 2016, 9089 samples were collected, comprising 3876 (43%) SDA-PCs and 5213 (57%) PPCs. Samples were recovered on the day of processing (at the end of the preparation process) and on the day of delivery (detailed in Table 1 ). In the PPCs, the mean platelet number was 1259 AE 171 × 10 all PCs, the leukocyte content was well below 1 × 10 6 per unit. sCD62P and sCD40L ( Fig. 1A and 1B) were examined to evaluate the level of platelet activation after each PC processing method. As shown in Fig. 1A , prestorage sCD62P levels were 167.6 AE 2.09 and 206.3 AE 2.7 ng/mL in the PPCs and SDA-PCs, respectively, indicating that platelet processing for PPC production could activate significantly fewer platelets than that for SDA-PCs (p < 0.0001). It can also be assumed that sCD40L and sCD62P may be elevated because a fixed number of platelets become very activated or many platelets all become a little more activated.
Similarly, prestorage sCD40L concentrations were 2,887 AE 25.43 and 4,283 AE 53.47 pg/mL in the PPCs and SDA-PCs, respectively (p < 0.0001) (Fig. 1B) . sCD62P (Fig. 1A) and sCD40L (Fig. 1B) were then measured in PCs during storage. The concentration of sCD62P and sCD40L varied significantly over time in both SDA-PCs and PPCs (p < 0.001). Interestingly, sCD62P and sCD40L increased more rapidly in PPCs than SDA-PCs at all time points.
The influence of different types of PAS (65%) on platelet activation during shelf-life was then evaluated. A total of 3,889 PPCs and 836 SDA-PC samples were stored in PAS-D and 1583 in PAS-E; sCD62P ( Fig. 2A) and sCD40L (Fig. 2B) were measured for each group during prestorage and storage. Concentrations of sCD62P and sCD40L varied significantly over time (both p < 0.0001). Interestingly, in contrast with sCD62P, the concentration of sCD40L in SDA-PCs in PAS-D was clearly greater than that of SDA-PCs in PAS-E or PPCs in PAS-D. On Day 5, the sCD62P concentrations were Table 1 ) are expressed in ng/mL (sCD62P) and pg/mL (sCD40L). Multiple comparisons were performed by two-way analysis of variance using the Bonferroni correction. ***p < 0.001. Table 1 ) are expressed in ng/mL (sCD62P) and pg/mL (sCD40L). Multiple comparisons were performed by two-way analysis of variance using the Bonferroni correction. **p < 0.01; ***p < 0.001.
208.1 AE 7.2, 140 AE 3.7, and 120.4 AE 4.1 ng/mL, respectively (PPCs PAS-D, SDA-PCs PAS-D, and SDA-PCs PAS-E), while sCD40L concentrations were 7573 AE 184.2, 7137 AE 286.9, and 3447 AE 119.9 ng/mL, respectively (PPCs PAS-D, SDAPCs PAS-D, and SDA-PCs PAS-E).
DISCUSSION
Platelet activation is lower in PPCs than SDA-PCs, based on concentrations of sCD62P and sCD40L secreted in PCs processed and stored for transfusion. The concentration of sCD40L and sCD62P varied significantly over time in PCs; however, their increases were more substantial in PPCs than SDA-PCs. Moreover, the level of sCD40L was greater in SDA-PCs stored in PAS-D than those in SDAPCs stored in PAS-E, consistent with previous reports.
14 -17 Storage of platelets in PAS has a number of benefits, including a reduction of serious adverse reactions. 18 As a low plasma content in PCs is a requirement for some pathogen inactivation processes, optimization of PAS has become a focus of interest. 19 Although differences can be demonstrated between PPCs and SDA-PCs, both processes conform to transfusion standards. Several reports indicate that platelets from apheresis and whole blood (buffy coats) are comparable both in terms of in vitro quality and clinically, although the comparison is debated. 11, 20 However, a French hemovigilance survey has clearly indicated the substantial superiority of PPCs over SDA-PCs in terms of tolerance. 21 PCs can be obtained from different sources as SDA-PCs and PPCs, and can be used for clinical applications, within the international directives and regulations set out in transfusion guidelines. Platelets from whole blood or apheresis are equivalent in quality; however, additional factors such as serious adverse reactions, donor accessibility, ethical considerations, cost, infectious risks, and donor comfort may affect the final choice of which method of platelet collection is used for transfusion. Little attention, if any, has been given to the impact of procedural changes on the anti-and proinflammatory lesions potentially inflicted by stored platelets. In certain countries, donors may be invited to donate more frequently than at 8-week intervals, allowing donations, in some circumstances, to be directed to the same recipient when chronically transfused, thus limiting recipient exposure to foreign material (antigens, proteins, and variants, etc.). However, for smooth inventory management, this is an extremely unlikely procedure in centralized systems serving a large body of hospitals. Further, in many countries-and this is the case in France-SDA donations are allowed at intervals of 8 weeks or more, as for all cell component donations. A preference for SDA over PPC has been expressed by stakeholders in transfusion medicine based on the less likely exposure of recipients to potential virus carriage (having one donor creates five times fewer opportunities than having five donors in a pool of 5). However, the overall safety measures in place to keep the lowest possible chance of transmitting a viral infection by transfusion, including the use of a single nucleic acid amplification test on each donation (as is done in France), evaluated by the annual residual risk of transmitting infection, 22 has rendered this argument less stringent than it used to be, especially when confronted with other parameters (fewer immune-inflammatory risks, cost-effectiveness, etc.). The preference of SDA over PPC and vice versa appears to be highly country or system dependent and most guidelines state no preference, provided a safe inventory is built up with close monitoring of quality management. The extent to which they affect patient outcome requires further investigation in clinical studies. Moreover, the extent to which anti-and proinflammatory lesions correlate with clinical outcomes is not fully understood. Further research will reveal the relationship between our in vitro data and clinical outcomes.
